[go: up one dir, main page]

ES2165910T3 - Administracion nasal y ocular de cetamina para el tratamiento del dolor y para la desintoxicacion. - Google Patents

Administracion nasal y ocular de cetamina para el tratamiento del dolor y para la desintoxicacion.

Info

Publication number
ES2165910T3
ES2165910T3 ES95913499T ES95913499T ES2165910T3 ES 2165910 T3 ES2165910 T3 ES 2165910T3 ES 95913499 T ES95913499 T ES 95913499T ES 95913499 T ES95913499 T ES 95913499T ES 2165910 T3 ES2165910 T3 ES 2165910T3
Authority
ES
Spain
Prior art keywords
pain
nasal
cetamine
detoxification
ocular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913499T
Other languages
English (en)
Inventor
Stuart L Weg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2165910T3 publication Critical patent/ES2165910T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTA INVENCION SE HALLA REFERIDA AL TRATAMIENTO DEL DOLOR CRONICO SIN NECESIDAD DE USAR NARCOTICOS Y AL AUTOTRATAMIENTO DE LOS PACIENTES AMBULATORIOS, TENIENDO INTERES TAMBIEN PARA FACILITAR LA DESINTOXICACION Y TRATAMIENTO DE LA ADICION A CIERTAS SUBSTANCIAS. POR TANTO SE TRATA DE UNA INVENCION DIRIGIDA EN LINEAS GENERALES A TRATAR EL DOLOR MEDIANTE LA ADMINISTRACION VIA NASAL DE UNA DOSIS DE KETAMINA PARA ALIVIAR EL DOLOR EN UN SUJETO QUE LO PADEZCA. ASIMISMO TIENE UTILIDAD PARA FACILITAR LA DESINTOXICACION Y TRATAMIENTO DE LOS SUJETOS ADICTOS A CIERTAS SUBSTANCIAS MEDIANTE LA ADMINISTRACION A ESTOS PACIENTES DE UNA DOSIS DE KETAMINA VIA NASAL UTIL PARA LA DESINTOXICACION Y EL TRATAMIENTO DE ADICIONES. EN UNA VERSION ULTERIOR SE FACILITA LA ADMINISTRACION PULMONAR DE KETAMINA MEDIANTE INHALACION. LA ADMINISTRACION VIA NASAL PRESENTA LA VENTAJA DE QUE EL PACIENTE PUEDE AUTOADMINISTRARSE EL MEDICAMENTO DE FORMA AMBULATORIA PARA TRATAR EL DOLOR O LA ADICION A UNA SUBSTANCIA. ADEMAS ES IMPORTANTE EL HECHO DE QUE LA ADMINISTRACION DE KETAMINA MEDIANTE SPRAYS NASALES O INHALADORES ES GENERALMENTE BIEN ACEPTADA SOCIALMENTE. ASI, POR EJEMPLO, UN PACIENTE QUE SUFRIA UN INSOPORTABLE DOLOR DE VESICULA QUE ERA INTRATABLE, CONSIGUIO CONTROLAR ESTE ATAQUE DE DOLOR CON LA ADMINISTRACION DE UNA DOSIS DE 16 A 32 MG DE KETAMINA.
ES95913499T 1994-02-25 1995-02-24 Administracion nasal y ocular de cetamina para el tratamiento del dolor y para la desintoxicacion. Expired - Lifetime ES2165910T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/201,756 US5543434A (en) 1994-02-25 1994-02-25 Nasal administration of ketamine to manage pain

Publications (1)

Publication Number Publication Date
ES2165910T3 true ES2165910T3 (es) 2002-04-01

Family

ID=22747152

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913499T Expired - Lifetime ES2165910T3 (es) 1994-02-25 1995-02-24 Administracion nasal y ocular de cetamina para el tratamiento del dolor y para la desintoxicacion.

Country Status (11)

Country Link
US (1) US5543434A (es)
EP (1) EP0751766B1 (es)
JP (1) JP4729148B2 (es)
AT (1) ATE206913T1 (es)
CA (1) CA2184077C (es)
DE (1) DE69523295T2 (es)
DK (1) DK0751766T3 (es)
ES (1) ES2165910T3 (es)
MX (1) MX9603633A (es)
PT (1) PT751766E (es)
WO (1) WO1995022965A2 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
ATE245024T1 (de) * 1995-02-24 2003-08-15 Stuart L Weg Anwendung von ketamin zur entgiftung
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
CA2230690C (en) * 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6197830B1 (en) * 1995-09-22 2001-03-06 Bruce M. Frome Method for achieving relief from sympathetically mediated pain
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
ES2302742T5 (es) * 2000-07-31 2011-10-10 Nycomed Danmark Aps Pulverizador nasal para suministrar una composición farmacéutica.
WO2002013886A2 (en) * 2000-08-15 2002-02-21 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US6805853B2 (en) * 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
JP4357842B2 (ja) * 2001-05-24 2009-11-04 アレックザ ファーマシューティカルズ， インコーポレイテッド 所定の吸入ルートによるアルプラゾラム、エスタゾラム、ミダゾラムまたはトリアゾラムの送出
JP2005503425A (ja) * 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
CN1551770A (zh) 2001-07-06 2004-12-01 ������ҩ�����޹�˾ 羟吗啡酮控释制剂
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
BR0205722A (pt) * 2001-07-06 2005-04-05 Penwest Pharmaceuticals Compan Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
WO2003051367A1 (en) * 2001-12-18 2003-06-26 Alexza Molecular Delivery Corporation Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
CA2506615A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040213828A1 (en) * 2003-04-23 2004-10-28 Smith David J. Pain relief lollipop compositions and methods
EP1625334B9 (en) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Percussively ignited self-contained heating unit
JP2007509115A (ja) * 2003-10-21 2007-04-12 ソセイ・アール・アンド・ディー・リミテッド オピエートの増強のための非オピエートの使用
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2006022714A1 (en) 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
WO2007111880A2 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20080275030A1 (en) * 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2009103150A1 (en) * 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
KR20150096370A (ko) 2012-08-23 2015-08-24 스튜어트 엘. 웨그 항불안제 조성물, 제형 및 사용방법
CN111643449A (zh) 2013-03-15 2020-09-11 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
CA2909357C (en) 2013-04-12 2022-02-22 Icahn School Of Medicine At Mount Sinai Use of ketamine to treat post-traumatic stress disorder
PL3043785T3 (pl) 2013-09-13 2022-02-28 National University Corporation Chiba University Zastosowanie R-ketaminy i jej soli jako środków farmaceutycznych
CN106714789A (zh) 2014-08-13 2017-05-24 詹森药业有限公司 用于治疗抑郁症的方法
JP2017528483A (ja) 2014-09-15 2017-09-28 ヤンセン ファーマシューティカ エヌ．ベー． Ｖａｌ６６Ｍｅｔ（ＳＮＰ ｒｓ６２６５）遺伝子型特異的投薬レジメン及びうつ病の治療のための方法
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20200297734A1 (en) 2015-06-19 2020-09-24 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
AU2016280161B2 (en) * 2015-06-19 2019-02-21 Harrow Ip, Llc Pharmaceutical compositions for anesthesiological applications
US10179136B2 (en) 2015-06-19 2019-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10555952B2 (en) 2015-06-19 2020-02-11 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10391102B2 (en) 2015-06-19 2019-08-27 Melt Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US10166240B2 (en) 2015-06-19 2019-01-01 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions and methods for anesthesiological applications
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
BR112020012473A2 (pt) 2017-12-22 2020-11-24 Janssen Pharmaceuticals, Inc. escetamina para o tratamento da depressão
WO2019152873A1 (en) 2018-02-02 2019-08-08 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
JP2021523228A (ja) 2018-05-04 2021-09-02 パーセプション ニューロサイエンス，インコーポレイティド 物質乱用の治療方法
US11154537B2 (en) 2018-08-10 2021-10-26 Eleusis Therapeutics Us, Inc. Method of treatment for ketamine infusion
BR112021017457A2 (pt) 2019-03-05 2021-11-16 Janssen Pharmaceuticals Inc Escetamina para o tratamento de depressão
EP3976012B1 (en) 2019-05-31 2024-03-20 Afyx Therapeutics A/S Intranasal administration of ketamine to cluster headache patients
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
EP4093388A1 (en) 2020-01-22 2022-11-30 Seelos Therapeutics, Inc. Reducing side effects of nmda antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334526A (en) * 1979-05-24 1982-06-15 Hamacher Edward N Method for administering a dissociative, unconscious type of anesthesia
US5132114A (en) * 1985-05-01 1992-07-21 University Of Utah Research Foundation Compositions and methods of manufacture of compressed powder medicaments
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration

Also Published As

Publication number Publication date
DK0751766T3 (da) 2002-02-11
WO1995022965A2 (en) 1995-08-31
MX9603633A (es) 1998-01-31
US5543434A (en) 1996-08-06
EP0751766A1 (en) 1997-01-08
CA2184077C (en) 2007-12-11
EP0751766B1 (en) 2001-10-17
DE69523295D1 (de) 2001-11-22
ATE206913T1 (de) 2001-11-15
DE69523295T2 (de) 2002-07-11
PT751766E (pt) 2002-04-29
JPH10500664A (ja) 1998-01-20
WO1995022965A3 (en) 1995-12-21
JP4729148B2 (ja) 2011-07-20
CA2184077A1 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
ES2165910T3 (es) Administracion nasal y ocular de cetamina para el tratamiento del dolor y para la desintoxicacion.
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
ES2177780T3 (es) Medicamentos para el tratamiento de enfermedades autoinmunes usando interferon tau.
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
ITBO930205A1 (it) Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
EP0744176A3 (en) Methods for inhibiting bone loss
AP9400647A0 (en) Medicaments for use in treatment of HIV or cancer patients.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
NO990450L (no) Behandling av sinnslidelser
IT1288399B1 (it) Medicamento per il trattamento terapeutico della maculopatia legata all'eta', della maculopatia non legata all'eta' e per la profilassi
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
DE59709079D1 (de) Topisches Arzneimittel auf Basis von Diclofenac
ITRM960096V0 (it) Dispositivo per il trattamento del corpo umano.
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
FR2759586B1 (fr) Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol
SE9803623D0 (sv) New therapeutic application
RU95111888A (ru) Способ лечения периферических поражений лицевого нерва
PT880971E (pt) Proteina estimuladora dos macrofagos para o tratamento de patologias do sistema nervoso
ES1031861Y (es) Dispositivo terapeutico para el alivio del dolor menstrual.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 751766

Country of ref document: ES